Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma
British Journal of Pharmacology · 2026-08 · 183 (16) · 4989-5017
DOI: 10.1111/bph.70415 ↗At a glance
Journal article in British Journal of Pharmacology, published online on 2026-05-19. Written by Xiaohui Yu and 7 co-authors. Institution: Department of Pathology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Chin…. Major MEDLINE topics: Carcinoma, Hepatocellular, Nanoparticles, Liver Neoplasms, Galactosyltransferases. Cited 1 times so far (Crossref); 76 references. Funded by: Hunan Provincial Natural Science Foundation of China, Scientific Research Project of Hunan Provincial Health Commission.
Abstract (original language)
Background and Purpose Aberrant protein glycosylation contributes significantly to hepatocellular carcinoma (HCC) progression. β ‐1,4‐Galactosyltransferase 3 (B4GALT3), an enzyme involved in glycosylation, is overexpressed in HCC and promotes tumour growth by stabilizing integrin β 1 (ITGB1). This study aimed to evaluate B4GALT3 as a therapeutic target and develop a precision nanotherapeutic approach for HCC. Experimental Approach Bioinformatics analyses using TCGA‐LIHC datasets identified B4GALT3 as a prognostic biomarker in HCC. Functional assays assessed the role of B4GALT3 in proliferation, migration, invasion and ITGB1 glycosylation in HCC cells. Subsequently, enzyme‐responsive 612‐AYR nanoparticles were engineered to deliver a specific B4GALT3 inhibitor selectively to tumour sites. The nanoparticles' biocompatibility, tumour‐targeting capability, retention and therapeutic efficacy were evaluated in both subcutaneous and orthotopic HCC mouse models. Key Results B4GALT3 enhanced HCC cell proliferation, migration, and invasion by increasing ITGB1 glycosylation, stabilizing its protein level and activating downstream signalling and cell‐cycle pathways. The 612‐AYR nanoparticles demonstrated excellent biocompatibility, tumour‐specific accumulation and prolonged retention in vivo. Treatment with these nanoparticles markedly suppressed tumour growth and metastasis in both mouse models through effective disruption of the B4GALT3–ITGB1 signalling axis. Conclusion and Implications Targeting aberrant glycosylation via enzyme‐responsive 612‐AYR nanoparticles delivering a B4GALT3 inhibitor presents a promising precision therapeutic approach for HCC. This integrated strategy combining glycosylation‐targeted molecular biology and advanced nanotechnology offers a novel paradigm for personalized cancer treatment, holding significant therapeutic and diagnostic potential.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Funding
- Hunan Provincial Natural Science Foundation of China
- Scientific Research Project of Hunan Provincial Health Commission
Cite
APA
Yu, X., Chen, X., Guo, H., Jin, X., Tan, P., Zeng, L., He, Y., & Li, J. (2026). Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma. British Journal of Pharmacology, 183(16), 4989-5017. https://doi.org/10.1111/bph.70415
Vancouver
Yu X, Chen X, Guo H, Jin X, Tan P, Zeng L, et al. Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma. British Journal of Pharmacology. 2026;183(16):4989-5017. doi:10.1111/bph.70415
BibTeX
@article{Yu2026,
author = {Yu, Xiaohui and Chen, Xiaoyan and Guo, Hui and Jin, Xia and Tan, Pingping and Zeng, Longwu and He, Yan and Li, Junjun},
title = {Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {16},
pages = {4989--5017},
doi = {10.1111/bph.70415}
}
EUVIMED